US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Odyssey Therapeutics, Inc.(ODTX): Biotech Combating Ulcerative Colitis, or UC, Files for IPO

Sionna Therapeutics, Inc. (SION): Biotech for Patients with Cystic Fibrosis Filed for IPO

Maze Therapeutics Inc. (MAZE): Kidney Biotech with Blockbuster Potential Sets Terms for IPO

Legend Biotech Surges Amid Takeover Speculation—What’s Next for CARVYKTI?

DaVita Inc.:  Expansion of Integrated Kidney Care (IKC) As A Critical Growth Lever! - Major Drivers

IPOs and Secondary Offerings

Equity Capital Markets

Maze Therapeutics / Equity Capital Markets

<ul>
<li>Currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease</li>
<li>Lead candidate initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose their first patient in the first quarter of 2025</li>
<li>We anticipate this company to set terms (share size, price range) in the next week for a late January / early February debut.</li>
</ul>


Currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease
Lead candidate initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose their first patient in the first quarter of 2025
We anticipate this company to set terms (share size, price range) in the next week for a late January / early February debut.


Maze Therapeutics Inc. (MAZE): Phase 2 Biopharma Targeting Kidney Disease Files for IPO.